US Stock Insider Trading | Pacific Biosciences disclosed 6 insider transactions on February 19

K-LinePoet · 2026-02-24T01:50:35+00:00

On February 19, 2026, Pacific Biosciences disclosed insider trading by several executives, with HENRY CHRISTIAN O selling 331,800 shares on February 17 and 140,900 shares on February 18. Other executives also made several sell transactions. The company focuses on developing advanced sequencing solutions to advance genomic research.

K-LinePoet

2026-02-24 01:50:35

Abstract generation in progress

On February 19, 2026, Pacific Biosciences (PACB) disclosed six insider trading transactions. Executive HENRY CHRISTIAN O sold 331,800 shares on February 18, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 19, 2026	Executive	Van Oene Mark	February 18, 2026	Sell	55,100	1.63	89,800
February 19, 2026	Executive	Van Oene Mark	February 17, 2026	Sell	129,800	1.58	204,500
February 19, 2026	Executive	HENRY CHRISTIAN O	February 18, 2026	Sell	141,900	1.63	229,500
February 19, 2026	Executive	HENRY CHRISTIAN O	February 17, 2026	Sell	331,800	1.58	522,900
February 19, 2026	Executive	Farmer Michele	February 17, 2026	Sell	35,200	1.58	55,500
February 19, 2026	Executive	Farmer Michele	February 18, 2026	Sell	15,000	1.63	24,400
August 20, 2025	Executive	Van Oene Mark	August 18, 2025	Sell	26,800	1.31	35,200
May 21, 2025	Executive	Farmer Michele	May 19, 2025	Sell	5,195	1.00	5,200.20
March 5, 2025	Executive	HENRY CHRISTIAN O	March 3, 2025	Sell	15,000	1.41	17,600
March 5, 2025	Executive	Van Oene Mark	March 3, 2025	Sell	6,486	1.41	9,125.80

[Company Profile]

Pacific Biosciences of California, Inc. was founded in 2000 in Delaware. The company is a leading life sciences technology firm designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to better understand genomes and ultimately solve complex genetic problems. The company’s research and development products and technologies are based on two highly differentiated core technologies focused on accuracy, quality, and integrity, including the existing HiFi long-read sequencing technology and the emerging Sequencing by Binding short-read sequencing technology. The company’s products encompass a wide range of applications, including human genomics sequencing, plant and animal sciences, infectious diseases and microbiology, oncology, and other emerging fields.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.